ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

Posted on by Shauna Dillon
  • 13th European Society of Gynecology (ESG) Congress: October 16-19 in Vienna, Austria.

Oral Presentation, Thursday, October 17 at 11:45 a.m. CET

“Is hormonal add-back necessary? A model-based analysis to guide gonadotropin-releasing hormone (GnRH) receptor antagonist use for management of endometriosis and uterine fibroids”

  • 10th American Conference on Pharmacometrics (ACoP) meeting: October 20‑23 in Orlando, FL

Poster Presentation, Tuesday, October 22 and Oral Presentation, Wednesday, October 23 at 9 a.m. EDT

“Model-based Dose Selection for a GnRH Receptor Antagonist in Endometriosis and Uterine Fibroids to Reduce Symptoms While Preventing Lumbar Spine Bone Mineral Density Loss”

Leave a Reply

Your email address will not be published. Required fields are marked *

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue